Suppr超能文献

与原发性甲状腺疾病相比,TSH 缺乏症的甲状腺功能减退症的诊断和治疗:垂体患者接受左甲状腺素替代治疗不足的风险更高。

Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine.

机构信息

Department of Diabetes and Endocrinology, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester, UK.

出版信息

Clin Endocrinol (Oxf). 2011 Jun;74(6):744-9. doi: 10.1111/j.1365-2265.2011.03984.x.

Abstract

OBJECTIVE

Achieving optimal thyroid hormone replacement is more difficult in TSH deficiency compared to primary hypothyroidism because of the inability to be guided by serum TSH levels. A combination of clinical symptoms and free thyroxine levels (fT4) are typically used to make a diagnosis and monitor replacement. We investigated the diagnosis of TSH deficiency in patients with pituitary disease and the adequacy of levothyroxine replacement compared with primary thyroid disease.

DESIGN

Using our department's clinical information system, we identified all patients with a diagnosis of any type of pituitary tumour who had been seen in clinic over a 2-year period. We divided the patients into those at high risk and low risk of TSH deficiency based on the presence of macroadenoma and/or intervention by surgery or radiotherapy. We compared fT4 values in these patients with values in patients with primary thyroid disease in our thyrotoxicosis shared-care scheme (TSC) and hypothyroid register within the same timescale, assessing only those samples considered euthyroid in which TSH was in the normal range.

RESULTS

A database query identified 525 patients with a pituitary tumour of whom 344 were considered at high risk of TSH deficiency. A free T4 (fT4) value was found for 514 patients (97·9%). TSC and thyroid register databases revealed fT4 values for comparison with simultaneous normal TSH in patients on no treatment (n = 3777 samples) or on levothyroxine alone (n = 11,805). fT4 levels overall were lower in pituitary patients than in equivalent controls. Of the high risk group not taking levothyroxine 17% had a free T4 ≤ 11 pmol/l compared to only 8·4% of untreated controls. Furthermore, 38·9% of patients on levothyroxine had a free T4 ≤ 13 pmol/l compared to 9·5% of controls on levothyroxine with previous thyrotoxicosis and 13·4% of controls with primary hypothyroidism. Median fT4 in controls on levothyroxine was 16 pmol/l and 20-80th centile range was 14-19 pmol/l.

CONCLUSION

Levothyroxine doses were generally under-replaced in pituitary patients compared to primary thyroid disease and the data imply that some untreated patients were actually TSH deficient. The distribution of fT4 in patients with primary thyroid disease on levothyroxine may guide optimum replacement levels in pituitary disease.

摘要

目的

与原发性甲状腺功能减退相比,TSH 缺乏症患者的甲状腺激素替代更难达到最佳水平,因为无法根据血清 TSH 水平进行指导。通常使用临床症状和游离甲状腺素(fT4)水平来诊断和监测替代治疗。我们调查了垂体疾病患者 TSH 缺乏的诊断以及与原发性甲状腺疾病相比,左甲状腺素替代的充分性。

设计

使用我们科室的临床信息系统,我们确定了在过去 2 年期间在门诊就诊的所有患有任何类型垂体肿瘤的患者。根据大腺瘤的存在和/或手术或放疗的干预,我们将患者分为 TSH 缺乏高风险和低风险人群。我们比较了这些患者的 fT4 值与我们甲状腺毒症共管方案(TSC)和甲状腺功能减退症登记册中同期原发性甲状腺疾病患者的 fT4 值,仅评估那些被认为是甲状腺功能正常的样本,其中 TSH 在正常范围内。

结果

数据库查询确定了 525 例垂体肿瘤患者,其中 344 例被认为 TSH 缺乏高风险。发现 514 例患者(97.9%)有游离甲状腺素(fT4)值。TSC 和甲状腺登记册数据库显示了与同时正常 TSH 的无治疗(n = 3777 个样本)或单独左甲状腺素治疗(n = 11805 个样本)的患者的 fT4 值进行比较。垂体患者的 fT4 水平总体低于对照组。未服用左甲状腺素的高风险组中,有 17%的游离 T4≤11pmol/L,而未经治疗的对照组中只有 8.4%。此外,38.9%的左甲状腺素治疗患者的游离 T4≤13pmol/L,而既往甲状腺毒症的左甲状腺素治疗对照组为 9.5%,原发性甲状腺功能减退症的对照组为 13.4%。对照组服用左甲状腺素的中位数 fT4 为 16pmol/L,20-80 百分位范围为 14-19pmol/L。

结论

与原发性甲状腺疾病相比,垂体患者的左甲状腺素剂量普遍替代不足,数据表明一些未经治疗的患者实际上存在 TSH 缺乏。原发性甲状腺疾病患者左甲状腺素治疗的 fT4 分布可能指导垂体疾病的最佳替代水平。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验